NASDAQ
09.04.26 | 21:59
15,000 US-Dollar
+3,34 % +0,485
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings | 5 | Seeking Alpha | ||
| 02.04. | Relay Therapeutics, Inc.: Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 | 9 | GlobeNewswire (USA) | ||
| RELAY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.03. | Raymond James reiterates Strong Buy on Relay Therapeutics stock | 29 | Investing.com | ||
| 16.03. | Oppenheimer reiterates Relay Therapeutics stock rating on trial data | 4 | Investing.com | ||
| 16.03. | Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients? | 6 | Benzinga.com | ||
| 16.03. | Relay Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.03. | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 220 | GlobeNewswire (Europe) | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| 13.03. | Guggenheim raises Relay Therapeutics price target on VM opportunity | 3 | Investing.com | ||
| 03.03. | Citizens reiterates Relay Therapeutics stock rating ahead of data | 13 | Investing.com | ||
| 26.02. | Relay Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 25.02. | Relay Therapeutics Earnings Preview | 13 | Benzinga.com | ||
| 20.02. | Relay Therapeutics, Inc.: Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 | 3 | GlobeNewswire (USA) | ||
| 04.02. | Relay Therapeutics' zovegalisib secures FDA BTD for advanced breast cancer | 14 | Pharmaceutical Technology | ||
| 03.02. | Relay Therapeutics, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 02.02. | Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors | 12 | Insider Monkey | ||
| 26.01. | Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns | 4 | Investing.com | ||
| 12.12.25 | Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug | 18 | Benzinga.com | ||
| 12.12.25 | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | 612 | GlobeNewswire (Europe) | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| 18.11.25 | Relay Therapeutics: Citizens bestätigt "Market Outperform"-Rating und Kursziel von 12 US-Dollar | 22 | Investing.com Deutsch | ||
| 18.11.25 | Citizens reiterates Market Outperform rating on Relay Therapeutics stock | 2 | Investing.com |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,10 | -0,57 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| EVOTEC | 4,527 | +0,02 % | Evotec-Aktie: Neuzugang könnte neue Hoffnungen wecken | Die Evotec-Aktie blieb in der schwachen Phase der Börsen stabil und konnte sich entgegen dem Trend leicht erholen. Am Donnerstag ging sie mit einem Gewinn von +2,2% aus dem Handel und steht bei rund... ► Artikel lesen | |
| BB BIOTECH | 48,750 | +1,14 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| MEDIGENE | 0,026 | -15,92 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,035 | +0,01 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,730 | -0,23 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| VALNEVA | 2,653 | +1,80 % | Valneva unter massivem Druck: Warum Insider bereits still und leise verkaufen - Was Sie jetzt noch wissen müssen | ||
| AMGEN | 304,40 | +0,18 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 7,330 | +0,55 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 291,00 | +0,41 % | Outset Medical adds former Stryker leader as new EVP of commercial | ||
| BIOGEN | 150,76 | -0,37 % | Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen | |
| ILLUMINA | 105,18 | -0,45 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,500 | +0,63 % | Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM | ||
| APOGEE THERAPEUTICS | 86,52 | +4,05 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARCELLX | 114,80 | +0,01 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen |
RELAY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,485 (+3,34 %) liegt der Kurs bei 15,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELAY THERAPEUTICS INC finden Sie auf Wallstreet Online.